{"filings":[{"id":2171521,"accession_number":"0001493152-26-036979","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2026-08-11T11:05:26+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xtant Q2 revenue down 35% to $23M, net loss $9.4M, cuts FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $23.0M vs $35.4M YoY; net loss $9.4M vs income $3.6M.","Adjusted EBITDA loss $2.7M vs +$6.9M; gross margin 57.9% vs 68.6%.","FY2026 revenue guidance cut to $99-103M from $101-105M.","Exclusive U.S. distribution deal with Dilon for HEMOBLAST Bellows; hired ~20-person sales team.","Cash $9.9M, debt $23.0M, revolver availability $0.7M as of June 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2133398,"accession_number":"0001493152-26-036586","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2026-08-07T20:15:47+00:00","items":["5.07","9.01"],"status":"ready","headline":"Xtant Medical shareholders elect six directors, ratify Grant Thornton, approve exec comp","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting held Aug 7, 2026; quorum 104,456,998 shares (74.47% of outstanding).","All six director nominees elected: Bakewell, Beeson, Browne, Jain, Lipschultz, Vizirgianakis.","Ratified Grant Thornton LLP as auditor for FY2026: 104,245,812 for, 30,112 against.","Advisory say-on-pay approved: 79,416,901 for, 1,030,090 against, 226,344 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":49962,"accession_number":"0001493152-26-022600","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2026-05-13T11:05:34+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Xtant Medical Q1 2026 net loss $3.1M; revenue falls to $20.9M, raises 2026 guidance to $101-105M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 revenue $20.9M vs $32.9M YoY; decline driven by asset sale to Companion Spine and license revenue ceasing.","Net loss of $3.1M vs net income of $58K in Q1 2025; non-GAAP adjusted EBITDA loss $1.6M vs +$3.0M.","Full-year 2026 revenue guidance raised to $101-105M from $95-99M reflecting HEMOBLAST incremental revenue.","Entered exclusive US distribution for Dilon Technologies' HEMOBLAST Bellows; hired approx. 20-person sales team.","Reduced total indebtedness by $13.3M; cash $12.2M, availability under revolver $11.8M as of March 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92938,"accession_number":"0001493152-26-016308","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Xtant Medical secures exclusive U.S. distribution rights for HEMOBLAST Bellows hemostat","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paid Dilon a $5.0M exclusivity fee; no minimum purchase requirements.","Hired approximately 20 Dilon U.S. sales personnel to commercialize the product.","HEMOBLAST Bellows is an FDA-approved collagen/thrombin/chondroitin sulfate hemostatic powder.","Addresses estimated $2.0 billion global addressable market for hemostatic products.","Xtant to update FY2026 guidance upon Q1 2026 earnings release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104185,"accession_number":"0001493152-26-013788","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xtant Medical reports FY2025 net income $5.0M vs loss $16.5M; revenue $134M (+14% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 revenue $134.0M (+14% YoY); net income $5.0M ($0.03 diluted EPS) vs net loss $16.5M in 2024.","Q4 2025 revenue $32.4M (+3% YoY); net income $0.1M vs net loss $3.2M; non-GAAP adjusted EBITDA $1.9M vs $0.4M.","Completed sale of non-core Coflex/CoFix assets and international hardware to Companion Spine for $21.4M cash.","Launched nanOss Strata synthetic bone graft and CollagenX bovine collagen product; total cash $17.3M at Dec 2025 + $10.5M received Feb 2026.","FY2026 revenue guidance $95M-$99M reflecting divestiture impact and cessation of license revenue; expects free cash flow positive."],"consensus_eps_estimate":-0.017,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":20884000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104184,"accession_number":"0001493152-26-008453","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Xtant receives $10.7M from Companion Spine; repays note, adjusts purchase price; total proceeds $21.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $10.7M on Feb 27, 2026 from Companion Spine: full repayment of $8.2M note plus accrued interest and working capital adjustments.","Total aggregate purchase price for Coflex/CoFix asset sale and Paradigm divestiture now $21.4M.","$2.8M of proceeds used to prepay portion of MidCap term loan; remaining principal $11.1M.","Original $19.2M purchase price included $8.2M note maturing Jan 31, 2026, now settled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104183,"accession_number":"0001493152-26-002569","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Xtant Medical extends Companion Spine Note and Paradigm payment dates to January 31, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Promissory note from Companion Spine for $8.2M extended to Jan 31, 2026 (originally Jan 15, 2026).","Purchase price adjustment payment of $1,742,000 for Paradigm Spine GmbH sale also extended to Jan 31, 2026.","Extensions relate to December 1, 2025 divestitures: Coflex/CoFix ($17.5M total) and Paradigm Spine ($1.7M base).","Note principal may be reduced by purchase price adjustments from the divestitures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120472,"accession_number":"0001493152-25-025963","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["2.01","2.04","7.01","9.01"],"status":"ready","headline":"Xtant completes sale of Coflex/CoFix and Paradigm OUS to Companion Spine for $19.2M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration $19.2M: $11.0M cash plus $8.2M unsecured promissory note maturing Jan 15, 2026.","Net cash proceeds used to prepay $8.0M of MidCap term loan; $14.4M remains outstanding, with up to $1.6M additional prepayment upon note repayment.","Pro forma revenue for nine months ended Sep 30, 2025 would be $85.2M (vs $101.6M reported); net income $6.8M (vs $4.9M) including estimated $3.9M gain.","CEO states net proceeds and operating cash flows expected to eliminate need for additional external capital.","Divestiture represents Xtant's shift to focus on core biologics business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120471,"accession_number":"0001493152-25-021538","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xtant Medical Q3 revenue $33.3M (+19% YoY); net income $1.3M vs loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $33.3M (19% YoY); gross margin 66.1% vs 58.4%; net income $1.3M ($0.01 EPS) vs loss $5.0M (-$0.04 EPS).","Adjusted EBITDA $4.5M vs loss $1.0M in prior year quarter; cash from operations $4.6M (vs $1.7M used).","FY25 revenue guidance reiterated $131-135M (+11-15% YoY).","Pending sale of non-core Coflex/CoFix assets and OUS businesses to Companion Spine expected to close by year-end 2025.","Launched CollagenX bovine collagen particulate for surgical wound closure; potential across entire biologics portfolio."],"consensus_eps_estimate":-0.0051,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":101570000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120470,"accession_number":"0001493152-25-021389","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"XTNT stockholders approve 12.3M share increase to 2023 equity plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["12,300,000 additional shares approved for 2023 Equity Incentive Plan, effective immediately.","Six director nominees elected with over 79M votes for each; no changes to board composition.","Ratification of Grant Thornton as auditor for FY 2025; advisory vote on exec compensation approved.","Stockholders voted 78.7M for 'every one year' frequency for future say-on-pay votes.","Quorum of 69.2% (96.9M shares) present at meeting held Nov 7, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137044,"accession_number":"0001641172-25-023109","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xtant Medical Q2 2025 revenue $35.4M (+18% YoY), net income $3.6M, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $35.4M up 18% YoY; gross margin improved to 68.6% from 62.1%.","Net income $3.6M ($0.02 diluted EPS) vs net loss $3.9M in Q2 2024.","Adjusted EBITDA $6.9M vs loss of $0.6M; operating cash flow $1.2M vs use of $5.1M.","FY2025 revenue guidance raised to $131-$135M (prior $127-$131M), growth 11%-15%.","Announced sale of non-core Coflex/CoFix/OUS assets to Companion Spine for ~$19.2M."],"consensus_eps_estimate":-0.0102,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":68315000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137043,"accession_number":"0001641172-25-022762","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Xtant Medical sets Nov 7, 2025 for annual meeting; proposal deadline Aug 18, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting scheduled for November 7, 2025; proxy statement expected around September 12, 2025.","Stockholder proposals for proxy inclusion under Rule 14a-8 must be received by August 18, 2025.","Director nominations and other proposals (non-Rule 14a-8) also due by August 18, 2025.","Universal proxy rule (Rule 14a-19) compliance deadline for nominees is September 8, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137042,"accession_number":"0001641172-25-022002","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xtant Medical elects two new directors; two directors resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Abhinav Jain and Tyler Lipschultz elected to Xtant Medical Board effective August 1, 2025.","Robert McNamara and Lori Mitchell-Keller resigned as directors effective same date; no disagreement.","Jain is an analyst at Nantahala Capital (49.1% owner) and serves on Aytu BioPharma and Talphera boards.","Lipschultz brings 35+ years orthopaedics/spine experience, previously at Orthofix, SeaSpine, NuVasive.","Appointments at Nantahala's request; Nantahala purchased 57M shares at $0.42 in April 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137041,"accession_number":"0001641172-25-018092","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Xtant sells Coflex/CoFix and OUS businesses to Companion Spine for $19.2M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration $19.2M: $11M cash at close plus $8.2M promissory note due Dec. 31, 2025.","Non-refundable $2.5M deposit paid; up to two additional $2.5M deposits if financing delays occur.","Net proceeds will reduce debt by $9.6M (prepayment to MidCap) and improve liquidity.","Closing expected Q3 2025, subject to Companion obtaining financing and other conditions.","Divestiture sharpens focus on core orthobiologics; certain employees will transition to buyer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154313,"accession_number":"0001641172-25-009664","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xtant Medical Q1 revenue $32.9M (+18% YoY), net income $58K, raises FY2025 guidance to $127-131M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $32.9M, up 18% vs Q1 2024; net income $58K vs net loss $4.4M prior year.","Adjusted EBITDA $3.0M vs loss $1.0M; cash from operations $1.3M vs use of $5.8M.","FY2025 revenue guidance raised to $127-131M (8-12% growth) from prior $126-130M.","Launched Trivium next-generation DBM allograft; elevated Mark Schallenberger to COO.","Terminated investor rights agreement with OrbiMed; completed secondary share sale led by Nantahala."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":32904000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154312,"accession_number":"0001641172-25-005078","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["1.02","2.02","5.01","7.01","8.01","9.01"],"status":"ready","headline":"Xtant completes secondary sale of 73.1M shares (52.5% stake) from OrbiMed to Nantahala; Q1 rev guidance $32.8-33.1M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["OrbiMed affiliates sold 73.1M shares (52.5% of outstanding) to Nantahala-led group at $0.42/share; OrbiMed now holds no Xtant shares.","Nantahala now owns 49.1% of Xtant (68.4M shares), becoming the largest stockholder and gaining effective control.","Investor rights agreement with OrbiMed terminated; company gains strategic and operational flexibility.","Preliminary Q1 2025 revenue expected $32.8M-$33.1M, up 18-19% YoY driven by orthobiologics and licensing.","Company loses NYSE American controlled company status; now must comply with independent director and committee rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154311,"accession_number":"0001641172-25-003711","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"OrbiMed affiliates sell ~73.1M Xtant shares at $0.42 to Nantahala; Nantahala to own 49.1%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OrbiMed affiliates selling 73.1M shares (all their XTNT shares) to Nantahala and other purchasers at $0.42/share.","After closing, Nantahala will hold 49.1% of outstanding shares, becoming the largest stockholder.","Company not a party to the stock purchase agreement; transaction privately negotiated.","Credit agreements amended to raise change-in-control threshold to 49.9% to accommodate Nantahala's ownership.","Company agrees to file resale registration statement for the shares within 30 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172897,"accession_number":"0001493152-25-009386","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xtant Medical reports 28% revenue growth in FY2024; guides FY2025 revenue $126M-$130M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $117.3M FY2024, up 28% YoY; Q4 revenue $31.5M, up 12%.","Net loss FY2024 $16.4M ($0.12/share) vs prior year net income $660k (incl $11.7M bargain gain).","Adjusted EBITDA loss FY2024 $2.3M vs loss $1.4M; Q4 positive $438k vs loss $695k.","Guidance: FY2025 revenue $126M-$130M (7-11% organic growth); expects free cash flow in H2 2025.","Post-year-end manufacturing/license deal for SimpliGraft: $1.5M upfront, minimum purchase obligations; annualized cost reductions >$5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189914,"accession_number":"0001493152-24-044756","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xtant Medical Q3 revenue $27.9M (+12% YoY); reaffirms FY2024 guidance $116-120M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $27.9M (+12% YoY); YTD revenue $85.8M (+36% YoY).","Net loss $5.0M vs net income $9.2M in Q3 2023, which included $11M bargain purchase gain.","Adjusted EBITDA loss $196K vs $440K gain; gross margin 58.4% down from 61.3%.","Reaffirmed FY2024 revenue guidance $116-120M, representing 27-31% annual growth.","Launched OsteoVive+ and Cortera system; signed license agreement for minimum $5.25M in fees."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":85754000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206423,"accession_number":"0001493152-24-034813","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xtant files updated Surgalign historical financials in support of S-3 registration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filing includes Surgalign's unaudited financials for H1 2023 and FY2022, and pro forma combined data for FY2023.","Surgalign H1 2023 revenue $30.3M (down from $41.2M); net income $5.8M vs loss $5.7M, driven by Coflex sale and warrant liability changes.","Pro forma info is presented for informational purposes and does not project future results.","No current operational update or guidance for Xtant is provided in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206422,"accession_number":"0001493152-24-030667","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Xtant Medical raises $5.0M via private placement of 7.8M shares at $0.64/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $5.0M from sale of 7,812,500 shares at $0.64/share to existing institutional investor.","Net proceeds to be used for working capital and general corporate purposes; closing expected August 9, 2024.","Craig-Hallum acted as sole placement agent; resale registration statement to be filed within 30 days of closing.","Directors and officers entered lock-up agreements restricting share sales for up to 90 days post-registration effective date.","Private placement exempt under Section 4(a)(2) and Rule 506 of Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206421,"accession_number":"0001493152-24-030662","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xtant Medical Q2 revenue up 48% to $29.9M; posts positive Adjusted EBITDA of $0.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $29.9M, +48% YoY; gross margin 62.1% (+50 bps); net loss $3.9M ($0.03/sh) vs $2.2M loss year ago.","Fifth consecutive quarter of positive Adjusted EBITDA: $0.5M vs $0.1M in prior year quarter.","Launched SimpliGraft and SimpliMax amniotic membrane allografts; added 15 new distributors and 20 IDN contracts in Q2.","Entered $5.0M private placement at $0.64/share on August 7, 2024; cash $5.4M at June 30, 2024.","Reaffirms FY2024 revenue guidance $116M-$120M (27%-31% annual growth)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":57816000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206420,"accession_number":"0001493152-24-028920","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Xtant Medical holds 2024 annual meeting; all three proposals approved by shareholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected with >90M votes for each; broker non-votes ~13.4M.","Ratification of Grant Thornton LLP as auditor: 105.7M for, 15.8K against, 137.9K abstain.","Advisory vote on executive compensation approved: 90.8M for, 1.4M against, 277.6K abstain, 13.4M broker non-votes.","Quorum of 81.25% of outstanding shares (105.9M shares) present at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223566,"accession_number":"0001493152-24-019864","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xtant Medical Q1 revenue up 55% to $27.9M; raises FY2024 revenue guidance to $116M-$120M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $27.9M, up 55% YoY from $17.9M.","Net loss of $4.4M ($0.03 per share) vs $2.1M loss in prior year.","Positive Adjusted EBITDA of $0.1M vs -$0.3M a year ago.","Gross margin improved 340 bps to 62.1%.","Full year 2024 revenue guidance raised to $116M-$120M from $112M-$116M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":27873000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223565,"accession_number":"0001493152-24-012143","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xtant Medical reports record FY 2023 revenue $91.3M, up 58% YoY; guides FY 2024 $112M-$116M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2023 revenue $91.3M, +58% YoY; organic growth 15%.","Net income $0.7M ($0.01/share) vs net loss $8.5M ($0.09) in 2022.","Non-GAAP adjusted EBITDA $1.0M in 2023, compared to loss of $3.0M in 2022.","FY 2024 revenue guidance $112M-$116M, representing 23%-27% growth.","Gross margin improved 540 bps to 60.8% for 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":27873000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242995,"accession_number":"0001493152-24-009247","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Xtant Medical upsizes revolver to $17M, extends maturity to 2029, removes EBITDA covenant","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving credit facility increased from $8M to $17M with MidCap Financial.","Term loan amended to include an additional $10M tranche for acquisitions at MidCap's discretion.","Maturity of both facilities extended to March 1, 2029.","Minimum Adjusted EBITDA requirement removed; net product revenue covenants reset.","Term loan interest margin reduced from 7.00% to 6.50%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260390,"accession_number":"0001493152-23-039986","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xtant Medical reports record Q3 revenue of $25M, raises FY2023 guidance to $88M-$91M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $25.0M, +73% YoY; organic growth 18%; acquisition contributions 55%.","Net income $9.2M ($0.07 EPS) vs net loss $2.4M ($0.03 loss) in Q3 2022.","Non-GAAP adjusted EBITDA $0.5M, improved from -$0.9M in prior-year period.","Gross margin expanded to 61.3% from 54.6% on production efficiencies and product mix.","FY2023 revenue guidance raised to $88M-$91M from prior $75M-$77M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":63195000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260388,"accession_number":"0001493152-23-038380","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K/A","filed_at":"2023-10-26T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Xtant acquires Surgalign assets; Surgalign reports Q1 2023 revenue $16.7M, net income $4.1M with going concern doubt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Surgalign Q1 2023 revenue $16.7M (down 19% YoY); net income $4.1M included $12.6M gain on Coflex sale.","Surgalign had $22.4M cash, $620M accumulated deficit; management expressed substantial doubt about going concern.","Surgalign not in compliance with Nasdaq listing requirements as of April 2023.","Xtant acquired Coflex/Cofix product lines for $17M cash; this 8-K/A provides Surgalign historical financials.","Pro forma condensed combined financial statements filed, giving effect to the acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260389,"accession_number":"0001493152-23-038003","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Xtant Medical acquires nanOss production ops from RTI Surgical for $2M cash plus contingent payments","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired equipment and inventory from RTI Surgical's synthetic bone graft business for $2M cash plus contingent payments based on future nanOss product sales.","Assumed lease for the nanOss production facility in Greenville, NC.","Previously acquired nanOss distribution rights and IP from Surgalign in August 2023.","CEO Sean Browne says full control will revive and grow nanOss, improving manufacturing capabilities and cash flows."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277682,"accession_number":"0001493152-23-029442","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2023-08-18T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Xtant Medical dismisses Plante & Moran, appoints Grant Thornton as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee appointed Grant Thornton LLP as independent auditor on August 15, 2023, replacing Plante & Moran.","Plante & Moran notified the audit committee it is evaluating whether to continue its SEC audit practice in the company's industry.","No disagreements or reportable events occurred during the two most recent fiscal years or the interim period preceding dismissal.","Audit reports for 2022 and 2021 were unqualified with no adverse opinions or modifications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277681,"accession_number":"0001493152-23-027585","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"Xtant Medical completes acquisition of Surgalign's hardware and biologics business for $5 million","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Xtant Medical acquired certain assets of Surgalign Holdings, Inc. for $5 million cash plus assumed liabilities under Bankruptcy Court supervision.","The acquisition includes inventory, intellectual property, contracts, equipment, and equity of Surgalign's international subsidiaries.","Xtant entered into Fourth Amendments to its credit agreements with MidCap Financial Trust and MidCap Funding IV Trust to permit the transaction.","Xtant issued a press release announcing closing and reiterated 2023 revenue guidance of $75-77 million.","The closing follows a Sale Order issued by the U.S. Bankruptcy Court for the Southern District of Texas on August 9, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277680,"accession_number":"0001493152-23-027280","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bankruptcy court approves Xtant Medical's $5M asset purchase from Surgalign","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Transaction approved by US Bankruptcy Court for Southern District of Texas on August 8, 2023.","Xtant acquires certain assets and assumed liabilities of Surgalign for $5M in cash.","Closing expected no later than September 1, 2023; court order to be entered shortly.","Surgalign filed for bankruptcy; Xtant named successful bidder at auction on July 28."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277679,"accession_number":"0001493152-23-026160","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xtant Medical Q2 revenue up 32% to $20.2M; raises FY 2023 guidance to $75-77M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $20.2M, up 32% YoY (14% organic, 18% from Coflex/CoFix acquisition).","Gross margin 61.6%, up from 54.8% in Q2 2022, driven by Coflex/CoFix contribution.","Net loss $2.2M ($0.02/share) vs $1.7M ($0.02) prior; adjusted EBITDA turned positive at $0.1M.","Raises FY 2023 revenue guidance to $75-77M from $73-75M, representing 29-33% annual growth.","CEO Sean Browne highlighted strength across channels and positive adjusted EBITDA ahead of expectations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":38176000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277678,"accession_number":"0001493152-23-025869","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2023-07-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xtant Medical wins auction for Surgalign's biologics and spinal fixation assets","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Won auction for Surgalign's domestic and international biologics and spinal fixation assets via initial bid from June 18 APA.","Closing expected after Bankruptcy Court sale hearing on Aug 8, 2023, but no later than Sep 1, 2023.","CEO Sean Browne expects assets to contribute to growth, complementing earlier Coflex acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277677,"accession_number":"0001493152-23-025769","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2023-07-28T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Xtant Medical shareholders approve 2023 equity plan and three charter amendments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 2023 Equity Incentive Plan with 5.5M new shares plus rollover from prior plan; effective through July 25, 2033.","Approved charter amendments: supermajority director vote to fix board >7, officer exculpation per DGCL, and exclusive forum change.","Re-elected six directors: Bakewell, Beeson, Browne, McNamara, Mitchell-Keller, Vizirgianakis with >87M votes each.","Ratified Plante & Moran as auditor for FY2023 (95.5M for, 11.6K against). Advisory say-on-pay passed with 87.2M votes for.","Amendments filed with Delaware Secretary of State on July 26, 2023; equity plan replaces 2018 plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277676,"accession_number":"0001493152-23-024228","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2023-07-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Xtant Medical extends deadline to terminate Surgalign asset purchase agreement to July 20, 2023","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["First Amendment extends Xtant's termination right deadline from July 10 to July 20, 2023 for reviewing disclosure schedules.","Amends mutual release provisions in the original Asset Purchase Agreement to clarify scope.","Original deal: Xtant pays $5M cash for hardware/biologics assets of Surgalign in Chapter 11.","Xtant is stalking horse bidder; auction may result in higher or better offers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277675,"accession_number":"0001493152-23-023229","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2023-07-03T23:59:59+00:00","items":["1.01","2.02","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Xtant Medical raises $15M via private placement of 20M shares at $0.75/share; provides Q2 2023 guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 20M shares at $0.75/share for gross proceeds of $15M.","Expected close on or about July 6, 2023; proceeds for working capital and general corporate purposes.","Investor presentation furnished as Exhibit 99.1 includes financial guidance for Q2 2023 (specifics not in filing).","Craig-Hallum Capital Group is acting as sole placement agent.","Directors and officers executed lock-up agreements; company to file resale registration statement within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295659,"accession_number":"0001493152-23-021783","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Xtant Medical enters $5M asset purchase agreement for Surgalign assets as stalking-horse bidder","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price $5M cash; 10% ($0.5M) in escrow; break-up fee of 3% if outbid.","Seller Surgalign filed Chapter 11 on June 19, 2023; sale under Bankruptcy Code Section 363.","Acquired assets include inventory, IP, contracts, equipment, and equity of international subsidiaries.","Transaction requires Bankruptcy Court approval and subject to auction with potential competing bids.","Xtant designated as stalking horse bidder; deal expected to close by September 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295658,"accession_number":"0001493152-23-018330","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Xtant Medical adopts amended bylaws with universal proxy rules, board expansion requires 75% approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved Third Amended and Restated Bylaws effective June 1, 2023, incorporating SEC universal proxy rules and recent DGCL amendments.","Stockholder nominations and proposals now require additional background information; proxy card color rule adopted (white reserved for Board).","Board expansion beyond seven members requires approval of at least 75% of directors then in office.","New emergency bylaw provisions allow greater flexibility during disasters or catastrophes as permitted by DGCL.","Notice by electronic transmission revised; advance stockholder consent requirement removed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295657,"accession_number":"0001493152-23-018040","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2023-05-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Xtant Medical appoints Lori Mitchell-Keller to Board of Directors effective May 16, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lori D. Mitchell-Keller elected to the Board, effective May 16, 2023; will serve on Compensation and Audit Committees.","Mitchell-Keller brings 30+ years software and industry experience, including VP at Google Cloud and President at SAP Industries.","She received a pro rata RSU award of 45,782 shares, vesting one year from June 15, 2023.","Chairman cites her operations, IT, and marketing expertise as valuable to Xtant's long-term growth strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295654,"accession_number":"0001493152-23-017793","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K/A","filed_at":"2023-05-16T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Xtant completes $17M acquisition of Surgalign SPV's Coflex/CoFix product lines","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price $17M in cash; funded with cash on hand and $5M from existing term loan.","Surgalign SPV 2021 revenue $17.8M, revenues in excess of direct expenses $8.0M.","Pro forma 2021 net income $0.4M vs Xtant standalone net loss $4.8M; accretive.","Acquired Coflex/CoFix FDA-approved for lumbar spinal stenosis, minimally invasive.","Transaction closed Feb 28, 2023; abbreviated financials filed May 16, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295656,"accession_number":"0001493152-23-015373","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xtant Medical Q1 revenue up 38% to $17.9M; initiates FY2023 guidance $73-75M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2023 revenue of $17.9M, up 38% YoY (29% organic, 9% from Coflex acquisition).","GAAP net loss improved to $2.1M ($0.02/shr) vs $2.2M ($0.03) in prior year.","Non-GAAP adjusted EBITDA loss narrowed to $0.3M from $0.9M in Q1 2022.","Full-year 2023 revenue guidance of $73M-$75M, representing 26%-29% annual growth.","Gross margin expanded to 58.7% from 58.3%, driven by Coflex contribution."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":17943000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295655,"accession_number":"0001493152-23-015371","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xtant Medical adds Jonn Beeson to board; directors Eggenberg and Rizzo resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jonn R. Beeson elected to board effective May 1, 2023; will chair newly formed Nominating and Corporate Governance Committee.","Beeson is a partner at Jones Day; receives RSU award of 52,049 shares vesting in one year and $20,000 retainer for committee chair.","Michael Eggenberg and Matthew Rizzo resigned as directors effective same date; no disagreement with company.","Resignations attributed to recent board additions, new chairman Stavros Vizirgianakis, and acquisition of Coflex/CoFix product lines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316196,"accession_number":"0001493152-23-006880","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2023-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xtant Medical Q4 revenue up 9% to $15.3M; full year net loss widens to $8.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $15.3M, up 9% YoY; full year revenue $58.0M, up 5% YoY.","Q4 net loss $2.2M ($0.02 per share), vs $2.3M ($0.03) in prior year.","Full year net loss $8.5M ($0.09 per share), up from $4.8M ($0.06) in 2021.","Non-GAAP Adjusted EBITDA full year loss $3.0M vs gain $0.3M in 2021.","Acquired Coflex product line to enhance fixation offering; financial details not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316195,"accession_number":"0001493152-23-006396","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["1.01","2.01","2.03","7.01","9.01"],"status":"ready","headline":"Xtant Medical acquires Coflex product line from Surgalign for $17M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired Coflex and CoFix product lines from Surgalign for $17M cash; closed Feb 28, 2023.","Coflex is only FDA PMA-approved interlaminar stabilization device for lumbar spinal stenosis; over 200,000 patients implanted.","Expected to add ~$14M in annual revenue with attractive margins; helps Xtant achieve profitability.","Funded with cash on hand and $5M additional borrowing under amended Term Credit Agreement (SOFR+7%, maturity May 2026).","Acquisition expands Xtant's ASC/outpatient offering and adds new distributors and trained surgeons."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316194,"accession_number":"0001493152-23-003251","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2023-02-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Xtant Medical sets July 26, 2023 annual meeting; proxy deadlines advanced","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting date set for July 26, 2023; proxy materials expected around June 5, 2023.","Stockholder proposals for inclusion in proxy must be received by February 24, 2023.","Other proposals and director nominations due February 11, 2023 (10 days after this filing).","Stockholders intending to use universal proxy rules must notify by May 27, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316193,"accession_number":"0001493152-23-000906","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Xtant Medical appoints Mark Schallenberger as COO effective Jan 16, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Schallenberger, previously COO at Surgenex, appointed COO at Xtant Medical effective Jan 16, 2023.","Annual base salary of $400,000 with bonus of up to 50% of base salary; option for 105,000 shares and RSUs for 89,000 shares.","Role is newly created, focused on operational modernization and product development.","Previously served at Xtant (formerly Bacterin) as Director of Scientific Affairs from 2010-2016."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334500,"accession_number":"0001493152-22-030277","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xtant Medical Q3 2022 revenue $14.5M (+5% YoY); net loss widens to $2.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $14.5M, up 5% from $13.8M in Q3 2021, driven by 12% biologics growth from OsteoFactor and OsteoVive Plus launches.","Gross margin improved to 54.6% from 52.2% on better capacity utilization.","Net loss of $2.4M ($0.03 loss per share) vs. $1.8M ($0.02) in prior-year period.","Non-GAAP adjusted EBITDA loss of $0.9M, compared to $0.6M loss a year ago.","CEO cited recent $9.75M private placement to support growth and expects full operating capacity by Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":42699000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334499,"accession_number":"0001493152-22-029849","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2022-10-28T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Xtant stockholders approve 8.5M share increase in 2018 Equity Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Second Amended and Restated 2018 Equity Incentive Plan on October 26, 2022.","Amendment increases shares available for issuance by 8,500,000 to a total capped by plan terms.","Other plan provisions unchanged; plan expires July 31, 2028 unless earlier terminated.","All six director nominees elected with >81.7M votes each; auditor ratified; say-on-pay approved.","Plan vote: 82,054,439 for, 809,383 against, 3,618 abstentions, 2,002,504 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334498,"accession_number":"0001493152-22-028040","cik":1453593,"company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","form_type":"8-K","filed_at":"2022-10-11T23:59:59+00:00","items":["3.02","7.01","9.01"],"status":"ready","headline":"Xtant Medical closes final $3M tranche of $9.75M private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second closing: ~6.2M shares + warrants for ~1.6M shares, raising ~$3.0M from accredited investors.","Total gross proceeds from both tranches ~$9.75M; first closing raised ~$6.75M.","Warrants immediately exercisable and expire on fifth anniversary of first closing.","Net proceeds to support working capital and other general corporate purposes.","Private placement led by Stavros Vizirgianakis; Fox Rothschild advised Xtant, Holland & Knight advised the investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":64379999.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-10-11T23:59:59+00:00|334498"}